Good glycaemic control: an international perspective on bridging the gap between theory and practice in type 2 diabetes

References

• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782–71Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782–7
   PubMed Web of Science ®Google Scholar
• Economist Intelligence Unit. Silent epidemic: an economic study of diabetes in developed and developing countries. London: Economist Intelligence Unit; 20072Economist Intelligence Unit. Silent epidemic: an economic study of diabetes in developed and developing countries. London: Economist Intelligence Unit; 2007
   Google Scholar
• NICE, National Institute for Clinical Excellence. Guidelines. Diabetic Med 2005;22( Suppl 1):5-63NICE, National Institute for Clinical Excellence. Guidelines. Diabetic Med 2005;22(Suppl 1):5-6
   PubMedGoogle Scholar
• AACE. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13( Suppl 1):1-684AACE. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1):1-68
   PubMedGoogle Scholar
• Asian-Pacific Type 2 Diabetes Policy Group, editor. Type 2 diabetes practical targets and treatments, 4th ed. Melbourne, Singapore: International Diabetes Institute and In vivo Communications; 20055Asian-Pacific Type 2 Diabetes Policy Group, editor. Type 2 diabetes practical targets and treatments, 4th ed. Melbourne, Singapore: International Diabetes Institute and In vivo Communications; 2005
   Google Scholar
• Anon. International Diabetes Federation global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabetic Med 2006;23:579-936Anon. International Diabetes Federation global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabetic Med 2006;23:579-93
   PubMedGoogle Scholar
• ADA. American Diabetes Association. . Standards of medical care in diabetes – 2007. Diabetes Care. 2007;30:S4-S417ADA. American Diabetes Association. Standards of medical care in diabetes – 2007. Diabetes Care. 2007;30:S4-S41
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–538UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53
   PubMed Web of Science ®Google Scholar
• Chuang LM, Tsai ST, Huang BY. et al. The status of diabetes control in Asia – a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabetic Med 2002; 19:978–859Chuang LM, Tsai ST, Huang BY. et al. The status of diabetes control in Asia – a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabetic Med 2002; 19:978–85
   PubMed Web of Science ®Google Scholar
• Raheja BS, Kapur A, Bhoraskar A. et al. DiabCare Asia – India study: diabetes care in India – current status. J Assoc Physicians India 2001;49:717–2210Raheja BS, Kapur A, Bhoraskar A. et al. DiabCare Asia – India study: diabetes care in India – current status. J Assoc Physicians India 2001;49:717–22
   PubMedGoogle Scholar
• Liebl A, Neiss A, Spannheimer A. et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany – results from the CODE-2 study. Exp Clin Endocrinol Diabetes 2002;110:10–611Liebl A, Neiss A, Spannheimer A. et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany – results from the CODE-2 study. Exp Clin Endocrinol Diabetes 2002;110:10–6
   PubMed Web of Science ®Google Scholar
• Charpentier G, Genes N, Vaur L. et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab 2003; 29:152–812Charpentier G, Genes N, Vaur L. et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab 2003; 29:152–8
   PubMed Web of Science ®Google Scholar
• Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002;45:23–2813Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002;45:23–28
   PubMed Web of Science ®Google Scholar
• Zwar NA, Hermiz O, Comino EJ. et al. Do multidisciplinary care plans result in better care for patients with type 2 diabetes?. Aust Fam Physician 2007;36:85–914Zwar NA, Hermiz O, Comino EJ. et al. Do multidisciplinary care plans result in better care for patients with type 2 diabetes?. Aust Fam Physician 2007;36:85–9
   PubMed Web of Science ®Google Scholar
• Mainous 3rd AG, Diaz VA, Saxena S. et al. Diabetes management in the USA and England: comparative analysis of national surveys. J R Soc Med 2006;99:463–915Mainous 3rd AG, Diaz VA, Saxena S. et al. Diabetes management in the USA and England: comparative analysis of national surveys. J R Soc Med 2006;99:463–9
   PubMed Web of Science ®Google Scholar
• Ko SH, Song KH, Kim SR. et al. Long-term effects of a structured intensive diabetes education programme (SIDEP) in patients with Type 2 diabetes mellitus – a 4-year follow-up study. Diabetic Med 2007;24:55–6216Ko SH, Song KH, Kim SR. et al. Long-term effects of a structured intensive diabetes education programme (SIDEP) in patients with Type 2 diabetes mellitus – a 4-year follow-up study. Diabetic Med 2007;24:55–62
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J (Clinical Research edition) 2000;321:405–1217Stratton IM, Adler AI, Neil HA. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J (Clinical Research edition) 2000;321:405–12
   PubMed Web of Science ®Google Scholar
• Schiel R, Muller UA. Intensive or conventional insulin therapy in type 2 diabetic patients? A population-based study on metabolic control and quality of life (The JEVIN-trial). Exp Clin Endocrinol Diabetes 1999;107:506–1118Schiel R, Muller UA. Intensive or conventional insulin therapy in type 2 diabetic patients? A population-based study on metabolic control and quality of life (The JEVIN-trial). Exp Clin Endocrinol Diabetes 1999;107:506–11
   PubMed Web of Science ®Google Scholar
• Standl E, Balletshofer B, Dahl B. et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39:1540–519Standl E, Balletshofer B, Dahl B. et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39:1540–5
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–1720Ohkubo Y, Kishikawa H, Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–17
   PubMed Web of Science ®Google Scholar
• Rhee SY, Kim YS, Oh S. et al. Diabcare Asia 2001 – Korea country report on outcome data and analysis. Korean J Intern Med 2005;20:48–5421Rhee SY, Kim YS, Oh S. et al. Diabcare Asia 2001 – Korea country report on outcome data and analysis. Korean J Intern Med 2005;20:48–54
   PubMedGoogle Scholar
• de Sonnaville JJ, Bouma M, Colly LP. et al. Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study. Diabetologia 1997;40:1334–4022de Sonnaville JJ, Bouma M, Colly LP. et al. Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study. Diabetologia 1997;40:1334–40
   PubMed Web of Science ®Google Scholar
• Eliasson B, Cederholm J, Nilsson P. et al. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996–2003. Diabetic Med 2005;22:1420–623Eliasson B, Cederholm J, Nilsson P. et al. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996–2003. Diabetic Med 2005;22:1420–6
   PubMed Web of Science ®Google Scholar
• Comaschi M, Coscelli C, Cucinotta D. et al. Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study. Nutr Metab Cardiovasc Dis 2005;15:204–1124Comaschi M, Coscelli C, Cucinotta D. et al. Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study. Nutr Metab Cardiovasc Dis 2005;15:204–11
   PubMed Web of Science ®Google Scholar
• Khaw KT, Wareham N, Luben R. et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). Br Med J (Clinical Research edition) 2001;322:15–825Khaw KT, Wareham N, Luben R. et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). Br Med J (Clinical Research edition) 2001;322:15–8
   PubMed Web of Science ®Google Scholar
• Selvin E, Marinopoulos S, Berkenblit G. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421–3126Selvin E, Marinopoulos S, Berkenblit G. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421–31
   PubMed Web of Science ®Google Scholar
• Redekop WK, Koopmanschap MA, Stolk RP. et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458–6327Redekop WK, Koopmanschap MA, Stolk RP. et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458–63
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329:977–8628The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329:977–86
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Engl J Med 2005;353:2643–5329Nathan DM, Cleary PA, Backlund JY. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Engl J Med 2005;353:2643–53
   PubMed Web of Science ®Google Scholar
• Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998;158: 134–4030Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998;158: 134–40
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996;124:90–631Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996;124:90–6
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE. et al. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994;154:2169–7832Klein R, Klein BE, Moss SE. et al. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994;154:2169–78
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE. et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. J Am Med Assoc 1988;260:2864–7133Klein R, Klein BE, Moss SE. et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. J Am Med Assoc 1988;260:2864–71
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med 2003;348:383–9334Gaede P, Vedel P, Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med 2003;348:383–93
   PubMed Web of Science ®Google Scholar
• Shichiri M, Kishikawa H, Ohkubo Y. et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Supppl 2):B21–B2935Shichiri M, Kishikawa H, Ohkubo Y. et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Supppl 2):B21–B29
   PubMedGoogle Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.36Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
   PubMed Web of Science ®Google Scholar
• TBC. Long-Term Veterans Affairs Diabetes Trial 200837TBC. Long-Term Veterans Affairs Diabetes Trial 2008
   Google Scholar
• Gerstein HC, Miller ME, Byington RP. et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med 2008;358: 2545–5938Gerstein HC, Miller ME, Byington RP. et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med 2008;358: 2545–59
   PubMed Web of Science ®Google Scholar
• Raskin P, Allen E, Hollander P. et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260–539Raskin P, Allen E, Hollander P. et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260–5
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T. et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269–7440Hermansen K, Davies M, Derezinski T. et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269–74
   PubMed Web of Science ®Google Scholar
• Selam JL, Koenen C, Weng W. et al. Improving glycemic control with insulin detemir using the 303 algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008;24:11–2041Selam JL, Koenen C, Weng W. et al. Improving glycemic control with insulin detemir using the 303 algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008;24:11–20
   PubMed Web of Science ®Google Scholar
• Hoelzel W, Weykamp C, Jeppsson JO. et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166–7442Hoelzel W, Weykamp C, Jeppsson JO. et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166–74
   PubMed Web of Science ®Google Scholar
• Miedema K. Towards worldwide standardisation of HbA1c determination. Diabetologia 2004;47:1143–843Miedema K. Towards worldwide standardisation of HbA1c determination. Diabetologia 2004;47:1143–8
   PubMed Web of Science ®Google Scholar
• The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Consensus statement on the worldwide standardisation of the HbA(1c) measurement. Diabetologia 2007;50:2042–344The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Consensus statement on the worldwide standardisation of the HbA(1c) measurement. Diabetologia 2007;50:2042–3
   PubMed Web of Science ®Google Scholar
• Monnier L, Grimaldi A, Charbonnel B. et al. Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory. Diabetes Metab 2004;30:35–4245Monnier L, Grimaldi A, Charbonnel B. et al. Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory. Diabetes Metab 2004;30:35–42
   PubMed Web of Science ®Google Scholar
• Prevost G, Phan TM, Mounier-Vehier C. et al. Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes Metab 2005;31:479–8546Prevost G, Phan TM, Mounier-Vehier C. et al. Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes Metab 2005;31:479–85
   PubMed Web of Science ®Google Scholar
• Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004;291:335–4247Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004;291:335–42
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–648Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–6
   PubMed Web of Science ®Google Scholar
• Sawin CT, Walder DJ, Bross DS. et al. Diabetes process and outcome measures in the Department of Veterans Affairs. Diabetes Care 2004;27:90–9449Sawin CT, Walder DJ, Bross DS. et al. Diabetes process and outcome measures in the Department of Veterans Affairs. Diabetes Care 2004;27:90–94
   Google Scholar
• Hanefeld M, Fischer S, Julius U. et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577–8350Hanefeld M, Fischer S, Julius U. et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577–83
   PubMed Web of Science ®Google Scholar
• Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab 2003;29:6S9–1851Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab 2003;29:6S9–18
   PubMed Web of Science ®Google Scholar
• Anon. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596–61552Anon. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596–615
   Google Scholar
• Gray A, Raikou M, McGuire A. et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) [United Kingdom Prospective Diabetes Study Group]. Br Med J (Clinical Research edition) 2000; 320:1373–853Gray A, Raikou M, McGuire A. et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) [United Kingdom Prospective Diabetes Study Group]. Br Med J (Clinical Research edition) 2000; 320:1373–8
   PubMed Web of Science ®Google Scholar
• Herman WH, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care 1998;21(Suppl 3):C19–C2454Herman WH, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care 1998;21(Suppl 3):C19–C24
   PubMedGoogle Scholar
• Kilpatrick E, Ørskov C, Berntorp K, et al., editors. HbA_1c: the gap between guidelines and clinical reality across eight countries. Amsterdam, The Netherlands: EASD; 200755Kilpatrick E, Ørskov C, Berntorp K, et al., editors. HbA1c: the gap between guidelines and clinical reality across eight countries. Amsterdam, The Netherlands: EASD; 2007
   Google Scholar
• Cabana MD, Rand CS, Powe NR. et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. J Am Med Assoc 1999;282:1458–6556Cabana MD, Rand CS, Powe NR. et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. J Am Med Assoc 1999;282:1458–65
   PubMed Web of Science ®Google Scholar
• Hofer TP, Zemencuk JK, Hayward RA. When there is too much to do: how practicing physicians prioritize among recommended interventions. J Gen Intern Med 2004;19:646–5357Hofer TP, Zemencuk JK, Hayward RA. When there is too much to do: how practicing physicians prioritize among recommended interventions. J Gen Intern Med 2004;19:646–53
   PubMed Web of Science ®Google Scholar
• Dixon AN, Raymond NT, Mughal S. et al. Prevalence of microalbuminuria and hypertension in South Asians and white Europeans with type 2 diabetes: a report from the United Kingdom Asian Diabetes Study (UKADS). Diab Vasc Dis Res 2006;3:22–558Dixon AN, Raymond NT, Mughal S. et al. Prevalence of microalbuminuria and hypertension in South Asians and white Europeans with type 2 diabetes: a report from the United Kingdom Asian Diabetes Study (UKADS). Diab Vasc Dis Res 2006;3:22–5
   PubMedGoogle Scholar
• Calvert MJ, McManus RJ, Freemantle N. The management of people with type 2 diabetes with hypoglycaemic agents in primary care: retrospective cohort study. Fam Pract 2007;24:224–959Calvert MJ, McManus RJ, Freemantle N. The management of people with type 2 diabetes with hypoglycaemic agents in primary care: retrospective cohort study. Fam Pract 2007;24:224–9
   PubMed Web of Science ®Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218–2460Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218–24
   PubMed Web of Science ®Google Scholar
• Singh R, Press M. Can we predict future improvement in glycaemic control? Diabetic Med 2008;25:170–361Singh R, Press M. Can we predict future improvement in glycaemic control? Diabetic Med 2008;25:170–3
   PubMed Web of Science ®Google Scholar
• Snoek FJ. Barriers to good glycaemic control: the patient's perspective. Int J Obes Relat Metab Disord 2000; 24(Suppl 3): S12–S2062Snoek FJ. Barriers to good glycaemic control: the patient's perspective. Int J Obes Relat Metab Disord 2000; 24(Suppl 3): S12–S20
   PubMedGoogle Scholar
• Ciechanowski PS, Katon WJ, Russo JE. et al. The patient–provider relationship: attachment theory and adherence to treatment in diabetes. Am J Psychiatry 2001;158:29–3563Ciechanowski PS, Katon WJ, Russo JE. et al. The patient–provider relationship: attachment theory and adherence to treatment in diabetes. Am J Psychiatry 2001;158:29–35
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V. et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) [UK Prospective Diabetes Study (UKPDS) Group]. J Am Med Assoc 1999;281:2005–1264Turner RC, Cull CA, Frighi V. et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) [UK Prospective Diabetes Study (UKPDS) Group]. J Am Med Assoc 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• Wroe J. The 3rd International DAWN summit: from research and practice to large-scale implementation. Pract Diabetes Int 2006;23:313–665Wroe J. The 3rd International DAWN summit: from research and practice to large-scale implementation. Pract Diabetes Int 2006;23:313–6
   Google Scholar
• Glasgow RE, Peeples M, Skovlund SE. Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures. Diabetes Care 2008;31:1046–5066Glasgow RE, Peeples M, Skovlund SE. Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures. Diabetes Care 2008;31:1046–50
   PubMed Web of Science ®Google Scholar
• Larranaga I, Arteagoitia JM, Rodriguez JL. et al. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the Basque Country, Spain. Diabetic Med 2005;22:1047–5367Larranaga I, Arteagoitia JM, Rodriguez JL. et al. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the Basque Country, Spain. Diabetic Med 2005;22:1047–53
   PubMed Web of Science ®Google Scholar
• Perria C. Strategies for the introduction and implementation of a guideline for the treatment of type 2 diabetics by general practitioners (GPs) of the Lazio region of Italy (IMPLEMEG study): protocol for a cluster randomised controlled trial [ISRCTN80116232]. BMC Health Serv Res 2004;4:1368Perria C. Strategies for the introduction and implementation of a guideline for the treatment of type 2 diabetics by general practitioners (GPs) of the Lazio region of Italy (IMPLEMEG study): protocol for a cluster randomised controlled trial [ISRCTN80116232]. BMC Health Serv Res 2004;4:13
   PubMedGoogle Scholar
• Schiel R, Franke S, Appel T. et al. Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN). Eur J Med Res 2004;9:391–969Schiel R, Franke S, Appel T. et al. Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN). Eur J Med Res 2004;9:391–9
   PubMed Web of Science ®Google Scholar
• Varroud-Vial M, Simon D, Attali J. et al. Improving glycaemic control of patients with Type 2 diabetes in a primary care setting: a French application of the Staged Diabetes Management programme. Diabetic Med 2004;21:592–870Varroud-Vial M, Simon D, Attali J. et al. Improving glycaemic control of patients with Type 2 diabetes in a primary care setting: a French application of the Staged Diabetes Management programme. Diabetic Med 2004;21:592–8
   PubMed Web of Science ®Google Scholar
• Rothman RL, Malone R, Bryant B. et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med 2005;118:276–8471Rothman RL, Malone R, Bryant B. et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med 2005;118:276–84
   PubMed Web of Science ®Google Scholar
• Krakow D, Feulner-Krakow G. LINDA: the diabetes self-management training programme for people with type 1 or type 2 diabetes. Eur Diabetes Nursing 2007;4:106–1272Krakow D, Feulner-Krakow G. LINDA: the diabetes self-management training programme for people with type 1 or type 2 diabetes. Eur Diabetes Nursing 2007;4:106–12
   Google Scholar
• Deakin TA, Cade JE, Williams R. et al. Structured patient education: the diabetes X-PERT programme makes a difference. Diabetic Med 2006;23:944–5473Deakin TA, Cade JE, Williams R. et al. Structured patient education: the diabetes X-PERT programme makes a difference. Diabetic Med 2006;23:944–54
   PubMed Web of Science ®Google Scholar
• Qaseem A, Vijan S, Snow V. et al. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Int Med 2007;147:417–2274Qaseem A, Vijan S, Snow V. et al. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Int Med 2007;147:417–22
   PubMed Web of Science ®Google Scholar
• CDA. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003, clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003. p. 2775CDA. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003, clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003. p. 27
   Google Scholar